Tower Research Capital (TRC)’s Entera Bio ENTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,008	Closed	-$54K	–	5855
2021 Q2	$54K	Sell	9,008 -12,991	-59%	-$48K	﹤0.01%	2967
2021 Q1	$84K	Buy	+21,999	New	+$50.6K	﹤0.01%	2718
2019 Q3	–	Sell	-862	Closed	-$3K	–	4189
2019 Q2	$3K	Sell	862 -100	-10%	-$388	﹤0.01%	3128
2019 Q1	$4K	Buy	962 +960	+48,000%	+$3.88K	﹤0.01%	3156
2018 Q4	$0	Buy	+2	New	+$10	﹤0.01%	3931

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tower Research Capital (TRC)'s ENTX Position: Q3 2021 in Review

Tower Research Capital (TRC) sold out of Entera Bio (ENTX) in Q3 2021, closing a stake of 9,008 shares — an estimated $54K sold.

Tower Research Capital (TRC) first reported a position in ENTX in Q4 2018 and held it in 5 quarters. The position peaked at $84K in Q1 2021. 14 funds tracked by Wall St. Rank hold ENTX as of Q3 2021.

Tower Research Capital (TRC) reported no remaining Entera Bio position as of Q3 2021 after selling out during the quarter.
Tower Research Capital (TRC) sold 9,008 Entera Bio shares in Q3 2021, an estimated $54K.
Tower Research Capital (TRC) first reported a position in Entera Bio in Q4 2018 and held it in 5 quarters.
Tower Research Capital (TRC)'s Entera Bio position peaked at $84K in Q1 2021.
14 funds tracked by Wall St. Rank held Entera Bio as of Q3 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2021, filed 15 Nov 2021.